Why Is Haemonetics Stock (HAE) Up Over 13% Today?
Haemonetics stock gained after the company released a new SEC filing covering a supply agreement with CSL Plasma.
Haemonetics Corp (HAE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Skylands Capital Charles Paquelet | 21,700 | $2,285,010 | -55% | 0.3% |
| 2. | Bailard Inc Thomas Bailard | 8,200 | $863,460 | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.56 | 1,400 | $98,784.00 | 24,757 | 2025-11-10 | Filing | |
| $80.93 | 4,000 | $323,720.00 | 12,048 | 2020-08-11 | Filing | |
| $35.00 | 60,000 | $2,099,754.00 | 105,867 | 2016-08-04 | Filing | |
| $32.73 | 412 | $13,482.70 | 31,522 | 2013-04-30 | Filing | |
| $32.73 | 615 | $20,125.88 | 17,279 | 2013-04-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.15 | 4,312 | $393,038.80 | 18,196 | 2024-07-26 | Filing | |
| $90.00 | 79 | $7,110.00 | 21,331 | 2024-07-12 | Filing | |
| $90.00 | 2,136 | $192,240.00 | 21,410 | 2024-07-11 | Filing | |
| $88.57 | 4,094 | $362,605.58 | 31,257 | 2024-05-29 | Filing | |
| $87.86 | 8,896 | $781,602.56 | 35,351 | 2024-05-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 453,579 | $47,761,869 | 0.05% | |
| 2. | 450,936 | $47,483,561 | 0.24% | |
| 3. | 59,256 | $6,239,657 | 0.6% | |
| 4. | 2,570,000 | $2,919,645 | 1.78% | |
| 5. | 26,190 | $2,757,807 | 0.32% |
News See All
Why Haemonetics (HAE) Could Benefit From Rising Demand for Plasma Therapies
Ariel Investments, an investment management company, released its "Ariel Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here.
Does Haemonetics (HAE) Have Enduring Growth Potential?
Aristotle Capital Boston, LLC, an investment advisor, released its first-quarter 2026 investor letter for “Small Cap Equity Fund”. A copy of the letter is available to download here. U.S.
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript May 8, 2026 Operator: Hello, and welcome to the Q4 2026 Haemonetics Corporation's earnings conference call.
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q1 2026 investor letter. A copy of the letter can be downloaded here.
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Haemonetics Corporation is among the best healthcare stocks to invest in.
10 Best Healthcare Stocks to Buy and Hold for 3 Years
In this article, we will be taking a look at the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. The first quarter of this year has seen a great deal of volatility in the equity markets.
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81
Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Haemonetics Corporation (NYSE:HAE) is among the most innovative healthcare stocks.
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth
Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S.
15 Innovative Healthcare Stocks to Buy According to Analysts
In this article, we will be taking a look at the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Hedge Fund Resource Center